119 related articles for article (PubMed ID: 26715063)
1. NRASQ61R immunohistochemistry: a new tool for mutational status screening in challenging melanoma samples.
Uguen A; Talagas M; Costa S; De Braekeleer M; Marcorelles P
Mod Pathol; 2016 Jan; 29(1):91-2. PubMed ID: 26715063
[No Abstract] [Full Text] [Related]
2. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.
Uguen A; Guéguen P; Legoupil D; Bouvier S; Costa S; Duigou S; Lemasson G; Ledé F; Sassolas B; Talagas M; Férec C; Le Maréchal C; De Braekeleer M; Marcorelles P
Hum Pathol; 2015 Nov; 46(11):1582-91. PubMed ID: 26297254
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.
Massi D; Simi L; Sensi E; Baroni G; Xue G; Scatena C; Caldarella A; Pinzani P; Fontanini G; Carobbio A; Urso C; Mandalà M
Mod Pathol; 2015 Apr; 28(4):487-97. PubMed ID: 25341653
[TBL] [Abstract][Full Text] [Related]
4. NRASQ61R immunohistochemistry detects both NRASQ61R and KRASQ61R mutations in colorectal cancer.
Jhuang JY; Yuan CT; Lin YL; Cheng ML; Liau JY; Tsai JH
Pathology; 2017 Jun; 49(4):387-390. PubMed ID: 28433252
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Detection of NRASQ61R Mutation in Diverse Tumor Types.
Dias-Santagata D; Su Y; Hoang MP
Am J Clin Pathol; 2016 Jan; 145(1):29-34. PubMed ID: 26712868
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma.
Barel F; Guibourg B; Lambros L; Le Flahec G; Marcorelles P; Uguen A
Acta Derm Venereol; 2018 Jan; 98(1):44-49. PubMed ID: 28660280
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
[TBL] [Abstract][Full Text] [Related]
8. NRASQ61R Mutation-specific Immunohistochemistry is Highly Specific for Either NRASQ61R or KRASQ61R Mutation in Colorectal Carcinoma.
Turchini J; Andrici J; Sioson L; Clarkson A; Watson N; Toon CW; Shepherd P; Ng D; Dixon-McIver A; Oei P; Gill AJ
Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):475-480. PubMed ID: 26862952
[TBL] [Abstract][Full Text] [Related]
9. Searching for the Chokehold of NRAS Mutant Melanoma.
Posch C; Vujic I; Monshi B; Sanlorenzo M; Weihsengruber F; Rappersberger K; Ortiz-Urda S
J Invest Dermatol; 2016 Jul; 136(7):1330-1336. PubMed ID: 27160069
[TBL] [Abstract][Full Text] [Related]
10. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity.
Newell F; Wilmott JS; Johansson PA; Nones K; Addala V; Mukhopadhyay P; Broit N; Amato CM; Van Gulick R; Kazakoff SH; Patch AM; Koufariotis LT; Lakis V; Leonard C; Wood S; Holmes O; Xu Q; Lewis K; Medina T; Gonzalez R; Saw RPM; Spillane AJ; Stretch JR; Rawson RV; Ferguson PM; Dodds TJ; Thompson JF; Long GV; Levesque MP; Robinson WA; Pearson JV; Mann GJ; Scolyer RA; Waddell N; Hayward NK
Nat Commun; 2020 Oct; 11(1):5259. PubMed ID: 33067454
[TBL] [Abstract][Full Text] [Related]
11. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.
Yakovian O; Sajman J; Arafeh R; Neve-Oz Y; Alon M; Samuels Y; Sherman E
Cancer Res; 2021 Mar; 81(5):1279-1292. PubMed ID: 33355187
[TBL] [Abstract][Full Text] [Related]
12. BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi.
Francis JH; Grossniklaus HE; Habib LA; Marr B; Abramson DH; Busam KJ
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):117-121. PubMed ID: 29332123
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of NRAS isoforms in Chinese melanoma patients.
Yan J; Xu L; Yu J; Wu X; Dai J; Xu T; Yu H; Guo J; Kong Y
Melanoma Res; 2019 Jun; 29(3):263-269. PubMed ID: 30489482
[TBL] [Abstract][Full Text] [Related]
14. Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma.
Puig-Butillé JA; Badenas C; Ogbah Z; Carrera C; Aguilera P; Malvehy J; Puig S
Exp Dermatol; 2013 Feb; 22(2):148-50. PubMed ID: 23362874
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of NRAS Signaling in Melanoma through Direct Depalmitoylation Using Amphiphilic Nucleophiles.
Vora HD; Johnson M; Brea RJ; Rudd AK; Devaraj NK
ACS Chem Biol; 2020 Aug; 15(8):2079-2086. PubMed ID: 32568509
[TBL] [Abstract][Full Text] [Related]
16. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
[TBL] [Abstract][Full Text] [Related]
17. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
[TBL] [Abstract][Full Text] [Related]
18. Melanoma proteomics suggests functional differences related to mutational status.
Trilla-Fuertes L; Gámez-Pozo A; Prado-Vázquez G; Zapater-Moros A; Díaz-Almirón M; Fortes C; Ferrer-Gómez M; López-Vacas R; Parra Blanco V; Márquez-Rodas I; Soria A; Fresno Vara JÁ; Espinosa E
Sci Rep; 2019 May; 9(1):7217. PubMed ID: 31076580
[TBL] [Abstract][Full Text] [Related]
19. Prognostic importance of mitochondrial markers in mucosal and cutaneous head and neck melanomas.
Soares CD; Morais TML; Carlos R; de Almeida OP; Mariano FV; Altemani A; de Carvalho MGF; Corrêa MB; Dos Reis RRD; Amorim LS; Jorge J
Hum Pathol; 2019 Mar; 85():279-289. PubMed ID: 30468799
[TBL] [Abstract][Full Text] [Related]
20. Human relevance of NRAS/BRAF mouse melanoma models.
Conde-Perez A; Larue L
Eur J Cell Biol; 2014; 93(1-2):82-6. PubMed ID: 24342721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]